Adjuvant Chemotherapy with Carmustine and Cisplatin for Patients with Malignant Gliomas

Overview

Journal J Neurooncol

Publisher Springer

Date 1992 Feb 1

PMID 1560258

Citations 10

Authors

W K Yung

T J Janus

M Maor

L G Feun

Affiliations

Soon will be listed here.

Abstract

Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy. Thirty-three patients were considered evaluable for responses, 17 had glioblastoma multiforme (GBM), 14 had anaplastic astrocytoma (AA) and 2 had anaplastic oligodendroglioma (AO). The median age of the evaluable patients was 47 years. The median time to tumor progression was 34.5 weeks, and the median survival for the entire group was 76 weeks. Early progression occurred more frequently in patients with glioblastoma than in those with AA or AO. Seventeen patients (55%) were alive at 18 months (6 GBM, 9 AA, 2 AO). Toxicity was mainly hematologic, otic and tolerable. The results suggest that further trial is warranted to assess the efficacy of alternating carmustine and cisplatin in conjunction with radiation therapy postoperatively in patients with malignant gliomas.

Citing Articles

A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.

Ahmed E, Bandopadhyay G, Coyle B, Grabowska A Cell Oncol (Dordr). 2018; 41(3):319-328.

PMID: 29492900 PMC: 5951876. DOI: 10.1007/s13402-018-0374-8.

Chemotherapy for malignant gliomas based on histoculture drug response assay : a pilot study.

Gwak H, Park H, Yoo H, Youn S, Rhee C, Lee S J Korean Neurosurg Soc. 2012; 50(5):426-33.

PMID: 22259689 PMC: 3259462. DOI: 10.3340/jkns.2011.50.5.426.

ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study.

Gwak H, Youn S, Kwon A, Lee S, Kim J, Rhee C J Neurooncol. 2005; 75(2):173-80.

PMID: 16132508 DOI: 10.1007/s11060-005-1858-8.

Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center.

Fazeny-Dorner B, Gyries A, Rossler K, Ungersbock K, Czech T, Budinsky A Wien Klin Wochenschr. 2003; 115(11):389-97.

PMID: 12879737 DOI: 10.1007/BF03040358.

Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.

Urban C, Benesch M, Pakisch B, Lackner H, Kerbl R, Schwinger W J Neurooncol. 1998; 39(1):71-80.

PMID: 9760072 DOI: 10.1023/a:1005966407408.

References

Walker M, Green S, Byar D, ALEXANDER Jr E, Batzdorf U, Brooks W . Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23):1323-9. DOI: 10.1056/NEJM198012043032303. View

Green S, Byar D, Walker M, Pistenmaa D, ALEXANDER Jr E, Batzdorf U . Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983; 67(2):121-32. View

Feun L, Lee Y, Yung W, Charnsangavej C, Savaraj N, Tang R . Phase II trial of intracarotid BCNU and cisplatin in primary malignant brain tumors. Cancer Drug Deliv. 1986; 3(2):147-56. DOI: 10.1089/cdd.1986.3.147. View

Stewart D, OBRYAN R, Al-Sarraf M, COSTANZI J, Oishi N . Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study. J Neurooncol. 1983; 1(2):145-7. DOI: 10.1007/BF00182960. View

. Antitumor activity of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979; 63(9-10):1453-8. View

Stewart D, Leavens M, Maor M, Feun L, Luna M, Bonura J . Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res. 1982; 42(6):2474-9. View

Levin V, Silver P, Hannigan J, Wara W, Gutin P, Davis R . Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990; 18(2):321-4. DOI: 10.1016/0360-3016(90)90096-3. View

Stanley K . Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980; 65(1):25-32. View

Levin V, Wilson C, Davis R, Wara W, Pischer T, Irwin L . A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg. 1979; 51(4):526-32. DOI: 10.3171/jns.1979.51.4.0526. View

10.

Nelson J, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N . Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer. 1983; 52(3):550-4. DOI: 10.1002/1097-0142(19830801)52:3<550::aid-cncr2820520327>3.0.co;2-c. View

11.

Aronin P, MAHALEY Jr M, Rudnick S, Dudka L, Donohue J, Selker R . Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med. 1980; 303(4):183-8. DOI: 10.1056/NEJM198007243030403. View

12.

Shapiro W . Therapy of adult malignant brain tumors: what have the clinical trials taught us?. Semin Oncol. 1986; 13(1):38-45. View

13.

Feun L, Stewart D, Maor M, Leavens M, Savaraj N, Burgess M . A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas. J Neurooncol. 1983; 1(2):109-13. DOI: 10.1007/BF00182955. View